Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50-Day Moving Average of $4.48
Capricor Therapeutics (NASDAQ:CAPR) Stock Passes Above 50-Day Moving Average of $4.48
Capricor Therapeutics Inc (NASDAQ:CAPR – Get Rating)'s stock price crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $4.48 and traded as high as $5.29. Capricor Therapeutics shares last traded at $5.20, with a volume of 170,510 shares traded.
在週二的交易中，Capricor Treateutics Inc.(納斯達克代碼：CAPR-GET Rating)的股價突破了50日移動均線。該股的50日移動均線為4.48美元，最高交易價格為5.29美元。Capricor Treateutics的股票最後交易價格為5.20美元，成交量為170,510股。
Analyst Ratings Changes
分析師評級發生變化
Separately, StockNews.com raised Capricor Therapeutics to a "sell" rating in a research note on Monday, May 23rd.
另外，StockNews.com在5月23日星期一的一份研究報告中將Capricor Treateutics的評級上調至“賣出”。
Capricor Therapeutics Stock Performance
Capricor Treateutics股票表現
The company has a 50-day moving average of $4.51 and a 200-day moving average of $4.08.
該公司的50日移動均線切入位在4.51美元，200日移動均線切入位在4.08美元。
Insider Buying and Selling at Capricor Therapeutics
Capricor Treateutics的內幕買賣
In other news, Director David B. Musket sold 17,775 shares of the company's stock in a transaction on Monday, June 27th. The stock was sold at an average price of $4.44, for a total transaction of $78,921.00. Following the completion of the sale, the director now directly owns 40,962 shares in the company, valued at approximately $181,871.28. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other news, Director David B. Musket sold 17,775 shares of the company's stock in a transaction on Monday, June 27th. The stock was sold at an average price of $4.44, for a total transaction of $78,921.00. Following the completion of the sale, the director now directly owns 40,962 shares in the company, valued at approximately $181,871.28. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director David B. Musket sold 28,215 shares of the company's stock in a transaction on Wednesday, June 29th. The stock was sold at an average price of $3.77, for a total value of $106,370.55. Following the sale, the director now owns 12,747 shares of the company's stock, valued at $48,056.19. The disclosure for this sale can be found here. 9.00% of the stock is currently owned by insiders.
另一則消息是，董事大衞·B·馬基特在6月27日(星期一)的一次交易中出售了17,775股該公司股票。該股以4.44美元的平均價格出售，總成交金額為78,921.00美元。出售完成後，董事現在直接擁有該公司40,962股，價值約181,871.28美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過以下鏈接獲得。另一則消息是，董事大衞·B·馬基特在6月27日(星期一)的一次交易中出售了17,775股該公司股票。該股以4.44美元的平均價格出售，總成交金額為78,921.00美元。出售完成後，董事現在直接擁有該公司40,962股，價值約181,871.28美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過以下鏈接獲得。此外，在6月29日週三的一筆交易中，董事大衞·B·馬斯基特出售了28,215股新浪微博股票。這隻股票的平均售價為3.77美元，總價值為106,370.55美元。交易完成後，董事現在持有該公司12,747股股票，價值48,056.19美元。此次拍賣的披露信息可在此處找到。該公司9.00%的股份目前由內部人士持有。
Institutional Trading of Capricor Therapeutics
Capricor Treateutics的機構交易
A number of institutional investors have recently added to or reduced their stakes in CAPR. Selective Wealth Management Inc. purchased a new stake in Capricor Therapeutics during the 1st quarter worth $732,000. Vanguard Group Inc. boosted its position in Capricor Therapeutics by 5.6% during the 1st quarter. Vanguard Group Inc. now owns 1,020,998 shares of the biotechnology company's stock worth $3,502,000 after purchasing an additional 54,260 shares during the period. Dimensional Fund Advisors LP boosted its position in Capricor Therapeutics by 54.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 148,768 shares of the biotechnology company's stock worth $510,000 after purchasing an additional 52,611 shares during the period. Bailard Inc. purchased a new stake in Capricor Therapeutics during the 2nd quarter worth $104,000. Finally, UBS Group AG boosted its position in Capricor Therapeutics by 326.0% in the 2nd quarter. UBS Group AG now owns 29,352 shares of the biotechnology company's stock valued at $102,000 after buying an additional 22,462 shares during the last quarter. 9.49% of the stock is owned by hedge funds and other institutional investors.
一些機構投資者最近增持或減持了CAPR的股份。選擇性財富管理公司在第一季度購買了Capricor Treateutics價值73.2萬美元的新股份。先鋒集團在第一季度將其在Capricor Treateutics的地位提高了5.6%。先鋒集團現在持有這家生物技術公司1,020,998股股票，價值3,502,000美元，在此期間又購買了54,260股。Dimension Fund Advisors LP在第一季度將其在Capricor Treateutics的頭寸增加了54.7%。Dimension Fund Advisors LP現在擁有這家生物技術公司148,768股股票，價值51萬美元，在此期間又購買了52,611股。Bailard Inc.在第二季度購買了Capricor Treateutics價值10.4萬美元的新股份。最後，瑞銀集團在第二季度將其在Capricor Treateutics的倉位提高了326.0%。瑞銀集團(UBS Group AG)現在擁有29,352股這家生物技術公司的股票，價值10.2萬美元，上個季度又購買了22,462股。該公司9.49%的股票由對衝基金和其他機構投資者持有。
Capricor Therapeutics Company Profile
Capricor治療公司簡介
(Get Rating)
(獲取評級)
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
卡布里科治療公司(納斯達克代碼：CAPR)是一家臨牀階段的生物技術公司，專注於治療罕見疾病的一流生物療法的發現、開發和商業化。Capricor的主要候選藥物CAP-1002是一種異基因細胞療法，目前正在臨牀開發中，用於治療Duchenne肌營養不良症。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Capricor Therapeutics (CAPR)
- Williams-Sonoma's High-End Consumers Are Still Spending
- Snowflake Stock Soars On Strong Results
- 3 Payroll Software Makers Set For Growth In 2023
- PENN Entertainment Stock is Reset and Ready to Rebound
- NVIDIA: A Top Choice In Bifurcated Chip Market?
- 免費獲取StockNews.com關於Capricor治療(CAPR)的研究報告
- 威廉姆斯-索諾馬的高端消費者仍在消費
- 雪花股票因業績強勁而飆升
- 3家薪資軟件製造商將在2023年實現增長
- 賓夕法尼亞娛樂公司股票重置，準備反彈
- NVIDIA：分流芯片市場的首選？
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Capricor Treateutics Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Capricor Treateutics和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。